NCT00662272已完成1 期
Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With Ascending Doses of JVRS-100 Adjuvant
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 128
- 试验地点
- 4
- 主要终点
- Comparison of adverse events between treatment groups
研究概览
简要总结
This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.
详细描述
The purpose of this trial is to evaluate the safety and tolerability of graded, ascending doses of JVRS-100 adjuvant when administered in combination with a vaccine antigen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •able to understand the study and provide written informed consent
- •be age 18 to 49 years
- •be in good general health, without significant medical history, physical examination findings, or abnormal laboratory results
- •be available for the study duration, including all planned follow-up visits
- •female subjects of child bearing potential must not be pregnant and agree to be correctly using an efficacious hormonal method of contraception or intrauterine device for at least 1 month before the study and during the study
排除标准
- •have allergy to eggs or other components of the vaccine
- •have had an influenza vaccine within 3 years preceding the screening visit
- •have a history of severe reaction of any kind to conventional influenza vaccines
- •have or suspected immunodeficiency disorder, including leukemia, lymphoma, generalized malignancy, or treatment with immunosuppressive medications, including corticosteroids, alkylating agents, antimetabolites, or radiation therapy
- •have a history of an autoimmune disorder, including systemic lupus, rheumatoid arthritis, scleroderma, other collagen vascular disease, multiple sclerosis, etc. Psoriasis limited to cutaneous manifestations is not an exclusion criterion.
- •have prior history of anaphylaxis to foods, hymenoptera stings, vaccines or drugs
- •have had transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 3 months of the Screening Visit or anticipated through the study period
- •have received another vaccine within 30 days preceding the screening visit or anticipated through the study period
- •have participation in another clinical trial within 60 days of the screening visit
- •have a positive serum or urine pregnancy test prior to vaccination or plan on a pregnancy during study period
- •have abnormalities on laboratory assessment
- •be seropositive to HIV or HCV or positive for HBsAg
- •be positive for anti-nuclear antibodies
- •have a physical examination indicating any clinically significant medical condition
- •have a body temperature >38.1°C (100.6°F) or acute illness within 3 days prior to vaccination
- •intention to travel out of the area prior to the study visit on Day 28 of the study
- •have a history of excessive alcohol consumption, drug abuse, significant psychiatric illness
- •have the intention to increase normal exercise routine, participate in contact sports or strenuous weight lifting or to initiate vigorous exercise from Screening until after Day 28 of the study
结局指标
主要结局
Comparison of adverse events between treatment groups
时间窗: Active Study Duration
Dose-response analysis of HAI geometric mean titers (GMT)
时间窗: 5 time points
次要结局
- Safety endpoints include between treatment group analyses of all safety parameters as described for the primary endpoint for each ascending dose cohort.(2 periods)
- Seroprotection and seroconversion rates to various antigens, distribution of antibody titers, duration of HAI antibody titers, and assessment of cross-reactive HAI responses against "drifted" strains.(5 time points)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy VolunteersInfluenzaNCT05152017St. Petersburg Research Institute of Vaccines and Sera75
已完成
3 期
Fluarix Immunogenicity and Safety TrialInfluenzaNCT00100399National Institute of Allergy and Infectious Diseases (NIAID)1,050
已完成
2 期
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineInfluenza, HumanInfluenza Viral InfectionsVaccine ReactionInfluenzaInfection VaccinationNCT05869201St. Petersburg Research Institute of Vaccines and Sera450
已完成
3 期
Study Comparing the Immune Response of Fluarix and Fluzone Influenza VaccinesInfluenzaNCT00197288GlaxoSmithKline1,847
已完成
1 期
Safety Study to Evaluate FluMist in Immunocompromised ChildrenCancerNCT00112112MedImmune LLC20